Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World March 19, 2013 Simon Hadlington	Global AstraZeneca restructuring will cost 1600 jobs The company's global research blueprint will now be centered on the creation of three 'strategic R&D centers' for small molecules and biologics, to be based in Cambridge in the UK, Gaithersburg in Maryland, US, and Molndal in Sweden, to be completed by 2016.
Chemistry World February 2, 2012 Andrew Turley	AstraZeneca to cut 7300 more jobs UK drugmaker AstraZeneca has announced plans to cut a further 7300 jobs to make annual savings of $1.6 billion by the end of 2014, a move that will cost the company $2.1 billion in the near term.
Chemistry World April 29, 2014 Phillip Broadwith	Pfizer courts AstraZeneca megamerger US-based pharma behemoth Pfizer has publically announced its intention to make a merger offer to the UK's AstraZeneca, in a deal valued at around $100 billion.
Chemistry World September 17, 2007	Uk Pharma Shifts Manufacturing Overseas Drug firm AstraZeneca has today reiterated that it will outsource drug manufacturing.
Chemistry World May 7, 2013 Phillip Broadwith	AstraZeneca site to become biotech hub The first three companies have already moved in, and more will hopefully follow to fill the space left by AZ as it relocates to Cambridge, UK.
Chemistry World April 2, 2013 Bibiana Campos Seijo	More job cuts... The news came in that AstraZeneca is to invest 330 million pounds in a new strategic R&D center and global headquarters in Cambridge, UK. Unfortunately, there is also a negative angle to this story.
Chemistry World June 19, 2013 Laura Howes	AstraZeneca announce new UK hub The new hub will consolidate all of AZ's UK activities, including biologics arm MedImmune, at the Cambridge Biomedical Campus on the southern outskirts of the city.
Chemistry World March 2, 2015 Phillip Broadwith	AstraZeneca to spin off anti-infectives research The new company's principal asset will be the novel gyrase inhibitor AZD0914, which is currently in Phase II clinical trials for treating gonorrhea.
Chemistry World September 3, 2014 Rajesh Parishwad	Piramal exits drug discovery in India India's Piramal Enterprises is exiting its early-stage drug discovery research and focusing on late clinical development, along with its core areas such as generics and contract research services.
Chemistry World May 31, 2013 Phillip Broadwith	Japanese pharma opens compound vaults Japanese pharmaceutical companies are opening up their libraries of experimental compound as part of a new partnership program. The initiative aims to find new drugs for malaria, tuberculosis and neglected tropical diseases.
Chemistry World December 10, 2014	Big pharma opens up abandoned drugs Sixty eight stalled pharmaceutical compounds are being made available for academic research through the UK Medical Research Council.
Chemistry World March 20, 2008 Richard Van Noorden	UK Drug Firms to Slash Research and Jobs The UK pharmaceutical industry is expecting to cut jobs and investment in R&D following an alarming slump in confidence in the UK market.
Chemistry World May 28, 2014 Phillip Broadwith	Time called on Pfizer -- AstraZeneca deal Pfizer's pursuit of a pharmaceutical megamerger has concluded with the US giant withdrawing its final offer two hours before the deadline set by the UK's takeover rules.
Chemistry World January 28, 2010 Nina Notman	AstraZeneca's workforce slashed again Pharma giant AstraZeneca is to cut another 8,000 jobs globally over the next four years - with approximately 1,800 additional research and development staff to be lost.
Chemistry World March 26, 2014 Phillip Broadwith	AstraZeneca boosts open innovation efforts Astrazeneca has launched a new web portal, bringing together new and existing open innovation programs. The aim is to make collaboration with academics, other companies, governments and non-government organizations easier.
Chemistry World November 6, 2013 Laura Howes	Novartis to shut Horsham site Last year, the firm slammed the UK for the high cost of conducting clinical trials in the country, warning that business would leave unless more incentives were introduced to encourage firms to carry out R&D.
Chemistry World April 16, 2010 Sean Milmo	Ineos starts UK chemicals exodus Ineos's decision to relocate its headquarters to Switzerland because of corporate taxation concerns may spark an exodus of chemical and pharmaceutical companies from having their headquarters in the UK.
Chemistry World June 11, 2008 James Mitchell Crow	GSK Job Cuts Hit Chemists GlaxoSmithKline is cutting the jobs of hundreds of scientists as it restructures its drug R&D operations.
InternetNews December 7, 2005 Colin C. Haley	Microsoft Plans Another $1.7B For India The company will put more money into India in hopes of getting more software out of it.
InternetNews December 6, 2005 Colin C. Haley	Microsoft Plans 30 New R&D Centers Microsoft Chairman Bill Gates kicked off a four-day India trip by outlining a plan to build 30 new innovation centers around the world, including one in the tech-heavy Indian city of Bangalore.
Chemistry World May 14, 2014 Andy Extance	Pfizer presses hard for AstraZeneca deal US pharma giant Pfizer is battling a backlash of suspicion and hostility across the world over its attempts to acquire its UK-headquartered rival AstraZeneca.
Chemistry World October 1, 2008 Victoria Gill	GSK to Cut 850 R&D Jobs GlaxoSmithKline has announced that up to 850 R&D jobs will be cut as it implements its new business strategy.
InternetNews September 9, 2009	EMC Opens Wallet to Expand R&D Efforts in India EMC plans to spend $1.5 billion over the next five years in Asia's third-largest economy.
Chemistry World April 3, 2014 Emma Stoye	Pharma giants plan new public--private collaborations AstraZeneca will partner with the Medical Research Council, in its new Cambridge site, while the Wellcome Trust Genome Campus will host a new center for target validation studies, jointly founded with the European Bioinformatics Institute and GlaxoSmithKline.
Chemistry World March 21, 2013 Phillip Broadwith	AstraZeneca partners with Moderna for $240 million Moderna has developed a way to use messenger RNA (mRNA), the molecule cells use to turn DNA into proteins, to stimulate the production of specific proteins in cells where disease has diminished or eliminated their ability to do so.
Chemistry World October 15, 2013 Dinsa Sachan	Supreme court ruling brings clinical trials to a halt in India The fate of 162 global clinical trials hangs in the balance, as the top Indian court has asked the government to provide more details on their approval process before they can proceed.
Chemistry World May 19, 2014 Phillip Broadwith	AstraZeneca refuses Pfizer's 'final' offer The US giant has described this proposal, valuing AZ at 70 billion pounds, as 'final' and says it 'cannot be increased'.
Chemistry World January 18, 2012 Patrick Walter	Shell shutters UK R&D site The research currently carried out at the facility will be transferred to overseas sites. The announcement has fueled concerns in the UK research community that the country's opportunity to become a high-tech economy is slipping away.
The Motley Fool September 10, 2008 Brian Orelli	Are Drug Companies Being Shortsighted With R&D? Cutting research and development spending could be like playing with fire for pharmaceutical companies.
Chemistry World July 15, 2008 Hepeng Jia	Testing Times for New Liver Drug AstraZeneca is set to start clinical trials of a liver cancer drug developed for Chinese patients.
Chemistry World February 20, 2013 Laura Howes	UK-India projects launched To coincide with the prime minister's visit to India, UK universities have announced a series of research partnerships and scholarships intended to boost the trade and education links between the UK and India.
Pharmaceutical Executive September 1, 2006 Jill Wechsler	Washington Report: New Partnerships Pursue Old Diseases A new wave of collaborations between industry, non-profits, and government seeks affordable treatments for neglected diseases around the world.
The Motley Fool May 15, 2006 Brian Gorman	AstraZeneca's Peer-Pressure Purchase The drug company seems to be paying a lot for Cambridge Antibody. Perhaps AstraZeneca didn't want to be left behind as its rivals bought up biotech technology -- but in its haste, it may be paying a steep price for what it's getting. Investors, take note.
The Motley Fool March 15, 2007 Chuck Saletta	The American Century Is Over As more R&D takes place overseas, the technological advances and profits will follow. So should investors.
Pharmaceutical Executive December 1, 2011	UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity.
Chemistry World February 2007 Mark Peplow	Science Stars Rise in the East Collaborate or die. That's the message of a series of reports from the independent thinktank Demos, claiming that British science is in danger of being sidelined unless it tries harder to work with booming Asian nations such as China, India and South Korea.
Chemistry World November 1, 2011 Sarah Houlton	A Shot in the Arm for Drugs for Neglected Diseases A new consortium of public and private sector partners has been launched by the World Intellectual Property Organization. Its aim is to share intellectual property that may help find drugs for malaria, tuberculosis and other neglected tropical diseases.
Pharmaceutical Executive September 1, 2011	Filling Front and Center in the Fight against TB Dr. Mel Spigelman, President and CEO of the TB Alliance, discusses the organization's priorities in developing treatments for tuberculosis.
Chemistry World August 15, 2012	The latent threat of tuberculosis Although TB was close to being eradicated in the developed world, it is a major problem in developing countries. With drug-resistant strains on the increase, Clare Sansom outlines the latest in the fight against this killer disease
IndustryWeek June 23, 2010	By The Numbers -- The Expense of R&D Among U.S.-owned businesses and U.S. affiliates of foreign companies, much of the R&D remained in the United States.
Chemistry World June 10, 2013 Phillip Broadwith	AstraZeneca stocks pipeline with acquisitions AZ is also buying Omthera Pharmaceuticals for an up-front payment of $323 million, with a potential $120 million in milestone payments on offer.
CFO October 1, 2003 Abe De Ramos	The China Syndrome U.S. companies are beginning to outsource technology research and development to India and China. Will a meltdown in tech jobs follow?
IEEE Spectrum November 2008 Hira & Ross	R&D Goes Global Hidden in corporate research budgets is a shift of R&D work to low-cost countries, particularly China and India.
Pharmaceutical Executive June 1, 2005 Jan Malek	When Two Heads are Better R&D president isn't one job-it's two. By appointing COOs for R&D with broad operational mandates, biotech and pharmaceutical companies can ensure that operational issues get the attention they urgently require.
Chemistry World August 29, 2007 Killugudi Jayaraman	India Announces Plans for Its First Nanopark Already the home for India's leading software and biotech firms, Bangalore is now aiming to attract businesses in another emerging area: nanotechnology.
IndustryWeek August 1, 2003 John Teresko	Outsourcing And R&D A global perspective and a knowledge network for acquiring technology will offer companies a competitive advantage.
Pharmaceutical Executive February 1, 2006 Joanna Breitstein	Breath of Hope: TB in Africa For the first time in decades, the pharmaceutical industry has tuberculosis drugs in the pipeline. But it will take more than new pills to solve the problem.
InternetNews December 5, 2005 Colin C. Haley	Intel India Earmarks $1B For India Intel will invest more than $1 billion in India over the next five years to increase its presence in a country that continues to evolve into an economic powerhouse. The chipmaker's five-year plan includes R&D and VC investment.
BusinessWeek June 19, 2006 Kripalani & Burrows	India: Why Apple Walked Away Plans for Apple's Indian tech support center have been scrapped.
BusinessWeek April 18, 2005 Manjeet Kripalani	India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India.